ABN Amro Investment Solutions Has $32.39 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• ABN Amro Investment Solutions increased its Gilead Sciences stake by 49% in the second quarter, adding 84,336 shares to hold 256,386 shares valued at approximately $32.4 million. Institutional investors collectively own 83.67% of Gilead.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year and above analyst expectations, while adjusted EPS of negative $6.75 surpassed estimates. The company also declared a quarterly dividend of $0.82, implying a 2.4% annual yield.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and an average price target of $158.04 versus the reported share price of $138.14. However, insiders sold 51,000 shares worth about $6.6 million over the past three months.

ABN Amro Investment Solutions increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 49.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 256,386 shares of the biopharmaceutical company's stock after purchasing an additional 84,336 shares during the quarter. ABN Amro Investment Solutions' holdings in Gilead Sciences were worth $32,392,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC boosted its position in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new stake in Gilead Sciences during the fourth quarter valued at $26,000. Wealth Preservation Advisors LLC grew its holdings in Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 81 shares during the period. Finally, Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the 4th quarter worth about $28,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Up 1.7%

NASDAQ GILD opened at $138.14 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The business has a 50 day moving average price of $129.93 and a 200-day moving average price of $136.44. The company has a market cap of $171.29 billion, a price-to-earnings ratio of -51.74 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. During the same period last year, the business earned $2.01 EPS. Gilead Sciences's quarterly revenue was up 10.6% compared to the same quarter last year. As a group, equities analysts expect that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is -122.85%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Strong Q2 operating trends: Analysts highlighted continued year-over-year sales growth led by Biktarvy and the HIV prevention franchise. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy and Livdelzi contributed to growth in oncology and liver disease. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI oncology collaboration: Gilead partnered with Nucleai to apply AI-powered tissue analytics to its antibody-drug conjugate programs. The technology could accelerate biomarker discovery and support more precise development of Gilead’s oncology pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Partnership and pipeline optionality: Gilead’s collaboration with Merck is being viewed as a potential growth engine, with recent clinical and regulatory progress supporting the strategic value of combining the companies’ capabilities. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Positive Sentiment: Assembly Biosciences collaboration: Assembly expanded development of ABI-6250 and reported a $115 million financing, while its cash runway includes a Gilead collaboration extension. The update supports continued advancement of programs associated with Gilead’s partnership. Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
• Positive Sentiment: Analyst and options signals: Analysts cited a consensus price target of $158.04, above the recent trading level, while unusually high call-option activity reflected increased bullish interest. Investors Purchase High Volume of Gilead Sciences Call Options Gilead Receives Consensus Target Price
• Neutral Sentiment: Valuation remains a debate: Despite a substantial multiyear return, commentary suggests Gilead still appears reasonably valued based on sales, leaving room for further gains if growth initiatives continue. Gilead Stock Still Looks Cheap on Sales
• Negative Sentiment: Mixed earnings-estimate revisions: Erste Group Bank modestly reduced its FY2026 EPS forecast to $(0.75) from $(0.74), below the broader consensus estimate of $(0.53), signaling some caution around near-term profitability. Erste Group Bank Estimates Gilead Sciences FY2027 Earnings

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O'day sold 15,000 shares of Gilead Sciences stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the transaction, the chief executive officer directly owned 617,567 shares in the company, valued at $81,185,357.82. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the sale, the insider directly owned 124,234 shares of the company's stock, valued at approximately $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 51,000 shares of company stock valued at $6,568,860. Corporate insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on GILD. Morgan Stanley cut their target price on Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating on the stock in a research report on Monday, July 27th. Wall Street Zen cut Gilead Sciences from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a "neutral" rating in a research report on Friday, April 17th. Needham & Company LLC reiterated a "buy" rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Leerink Partners lowered shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Twenty-four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $158.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source